Molecular genetics diagnostic company Mainz Biomed raised USD 50 million through a Pre-Paid Advance Agreement (PPA) with Yorkville Advisors Global. Additionally, it has entered a USD 5.5 million Promissory Note, with USD 5.0 million already funded at the time of closing. This brings the total funds raised to USD 72.5 million.

The funding will provide support for Mainz Biomed's commercial and product development plans, offering flexibility for strategic and opportunistic operations.

Mainz Biomed is a specialized company focused on early cancer detection, with a particular emphasis on colorectal cancer (CRC). Its flagship product, ColoAlert, is an at-home screening kit for CRC. The company follows a unique business model by partnering with third-party laboratories for test kit processing. In addition to commercializing ColoAlert, Mainz Biomed is actively conducting clinical studies for a CRC screening test. Furthermore, it has an early-stage product pipeline that includes a screening test specifically designed for pancreatic cancer.